NFKB1 and ovarian cancer: In addition, NF‐kB activation upregulates PDL1, a negative regulator of immune response to tumor cells [54], and UBE2N inhibition might then help elicit immune‐mediated antitumor response in vivo, or sensitize to anti‐PDL1 therapies currently studied in ovarian cancer [55].